



Astec LifeSciences Ltd.

Dated: 4th May, 2016

To,
The Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

To,
The Department of Corporate Services
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138"

Ref: "ASTEC"

Sub: Outcome of the Board Meeting

Dear Sir,

This is to inform you that the Board of Directors of the Company at its Meeting held today, i.e. on 4th May, 2016, *inter alia*, have considered the following:-

- A. On recommendation of the Audit Committee the Board of Directors has approved:-
- a) Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended 31st March, 2016 (Enclosed);
 - b) Statement of Assets & Liabilities as on 31st March, 2016 (Enclosed);
- B. Audit Report on Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended 31st March, 2016 and Form A as per Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Enclosed);
- C. On recommendation of the Nomination and Remuneration Committee the Board of Directors has appointed Mr. Arijit Mukherjee (DIN: 07334111) as a Whole Time Director of the Company with immediate effect, subject to approval of Shareholders;
- D. That the Compensation Committee at its Meeting held today i.e. on 4th May, 2016 has allotted 27,600 Equity Shares of Face Value Rs.10/- each to the employees of the Company on exercise of Options granted to them, at an exercise price of Rs.34/- per Equity Share, under Astec Employee Stock Options Plan, 2012, as fully paid-up.

-The above 27,600 Equity Shares would rank *pari passu* with the existing Equity Shares of the Company in all respects including dividend entitlement.



Regd. Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone: +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail : info@astecsls.com
Website : www.astecsls.com
CIN : L99999MH1994PLC076236



Astec LifeSciences Ltd.

- With this allotment the total paid-up capital of the Company stands at Rs.19,48,26,550/- (Rupees Nineteen Crore Forty Eight Lac Twenty Six Thousand Five Hundred and Fifty Only) (divided into 1,94,82,655 Equity Shares of Rs.10/- each)

Please take the above information on your records.

Thanking you,

Yours Sincerely,

FOR ASTEC LIFESCIENCES LIMITED

Tejal Jariwala

Company Secretary & Compliance Officer

ACS 32441



Encl: A/a



ISO 9001:2008



ISO 14001:2004



OHSAS 18001:2007

Regd. Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone : +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail : info@astecsls.com
Website : www.astecsls.com
CIN : L99999MH1994PLC076236



Astec LifeSciences Limited
CIN : L99999MH1994PLC076236

Registered Office : 7th Floor, Elite Square, 274, Perin Nariman Street, Fort, Mumbai- 400001, Maharashtra
Website: www.astecsls.com, Tel no.022-61205600, Fax no.- 022-22618289, Email id: info@astecsls.com

Audited Financial Results for the Quarter and Year Ended 31st March, 2016

PART Sr. No	Particulars	STANDALONE					CONSOLIDATED				
		Rs. In Lac (Except for per share data)					Rs. In Lac (Except for per share data)				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		31/03/2016	31/12/2015	31/03/2015	31/03/2016	31/03/2015	31/03/2016	31/12/2015	31/03/2015	31/03/2016	31/03/2015
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income from Operations										
	a) Net Sales / Income from operations (Net of Excise Duty)	8,565.51	4,357.60	9,054.58	24,579.66	25163.64	8,678.95	4,357.60	9,270.08	25,928.70	26,688.17
	b) Other Operating Income	39.03	49.36	106.84	218.66	182.18	163.53	49.36	14.56	320.28	93.41
	Total Income from Operations (net)	8,604.54	4,406.96	9,161.42	24,798.32	25,345.82	8,842.47	4,406.96	9,284.64	26,248.99	26,781.58
2	Expenses										
	a) Cost of materials consumed	5615.18	3222.54	5,136.08	16,372.44	15655.91	5,653.29	3,222.54	4,908.51	18,613.41	17,801.74
	b) Changes in inventories of finished goods and work-in-progress	303.28	503.93	828.09	516.86	241.20	351.42	503.93	768.35	(921.22)	72.40
	c) Employee benefits expense	338.89	573.55	377.70	1,491.61	1,143.93	338.89	573.55	351.21	1600.16	1227.44
	d) Depreciation and amortisation expense	405.45	319.28	53.33	1,351.66	1,199.81	398.52	320.44	103.20	1384.84	1268.73
	e) Other expenses	927.12	1348.06	1,027.61	3,932.22	2,952.27	918.01	1,345.36	1,371.62	4280.91	2175.45
	Total Expenses	7,589.92	5,967.37	7,422.80	23,664.80	21,193.11	7,660.14	5,965.83	7,502.88	24,958.09	22,545.76
3	Profit/ (Loss) from operations before other income, finance cost and exceptional items (1-2)	1,014.62	(1,560.40)	1,738.62	1,133.53	4,152.71	1,182.34	(1,558.87)	1,781.75	1,290.89	4,235.82
4	Profit / (Loss) from ordinary activities before finance cost and exceptional items	1,014.62	(1,560.40)	1,738.62	1,133.53	4,152.71	1,182.34	(1,558.87)	1,781.75	1,290.89	4,235.82
5	Finance costs	317.87	328.94	334.69	1,249.46	1,210.09	314.85	328.94	321.46	1,280.62	1,284.00
6	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (4-5)	696.75	(1,889.34)	1,403.93	(115.93)	2,942.62	867.48	(1,887.80)	1,460.29	10.28	2,951.82
7	Exceptional items	274.67	385.76	1693.83	1,697.99	1,693.83	274.67	385.76	1693.83	1,697.99	1,693.83
8	Profit / (Loss) from ordinary activities before tax (6-7)	422.08	(2,275.10)	(289.90)	(1,813.92)	1,248.79	592.81	(2,273.57)	(233.54)	(1,687.71)	1,257.99
9	Tax expense	985.50	(718.75)	74.66	159.62	(228.64)	986.82	(718.28)	81.37	162.27	(220.27)
10	Net Profit / (Loss) from ordinary activities after tax (8-9)	(563.42)	(1,556.36)	(364.56)	(1,973.54)	1,477.43	(394.01)	(1,555.28)	(314.91)	(1,849.97)	1,478.26
11	Extra-ordinary items	(27.83)	143.61	(639.62)	49.06	-	(20.45)	143.61	(639.62)	56.45	-
12	Net Profit / (Loss) for the period (10 - 11)	(535.59)	(1,699.97)	275.06	(2,022.60)	1,477.43	(373.56)	(1,698.89)	324.71	(1,906.42)	1,478.26
13	Minority Interest	-	-	-	-	-	12.59	0.37	0.03	9.97	0.72
14	Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (12-13)	(535.59)	(1,699.97)	275.06	(2,022.60)	1,477.43	(386.15)	(1,699.26)	324.68	(1,916.40)	1,477.54
15	Paid-up equity share capital (Face Value Rs.10/-)	1,945.51	1,945.51	1,945.51	1,945.51	1,945.51	1,945.51	1,945.51	1,945.51	1,945.51	1,945.51
16	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	11,705.64	-	-	-	-	11,588.13
17	Earnings Per Share (before extra-ordinary items) - Basic	(2.90)	(8.00)	(1.95)	(10.14)	7.91	(2.74)	(8.00)	(1.69)	(9.56)	7.91
18	Earnings Per Share (before extra-ordinary items) - Diluted	(2.88)	(7.97)	(1.95)	(10.10)	7.91	(2.73)	(7.97)	(1.69)	(9.52)	7.91
19	Earnings Per Share (after extra-ordinary items) - Basic	(2.75)	(8.74)	1.47	(10.40)	7.91	(2.64)	(8.73)	1.74	(9.85)	7.91
20	Earnings Per Share (after extra-ordinary items) - Diluted	(2.74)	(8.71)	1.47	(10.35)	7.91	(2.63)	(8.71)	1.74	(9.81)	7.91

Notes:

- 1 The above results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its Meeting held on 4th May, 2016.
- 2 The above results have been audited by Statutory Auditors of the Company.
- 3 Above financials include audited financial results of Behram Chemicals Pvt. Ltd. (65.63% subsidiary) for the Year Ended 31st March, 2016, unaudited financials of Astec Europe Sprl (50.10% subsidiary) for the Year Ended 31st December, 2015 and unaudited financial results of Comercializadora Agricola Agroastrachem Cia Ltda (100% Subsidiary) for the Year Ended 30th September, 2015.
- 4 Pursuant to the Share Purchase Agreement, the entire stake of the Company in Astec Crop Care Private Limited ("ACCPL") has been sold off during the year, consequent to which ACCPL has ceased to be a Subsidiary of the Company. The results of ACCPL are not consolidated with effect from 1st October, 2015. Therefore, the Consolidated results for the Year / Period are not comparable to that extent.
- 5 Diluted Earning per share (EPS) has been restated for the Quarter/period Ended 31st December, 2015 and 31st March, 2015 in line with the provision of AS - 20 on account of Astec Employee Stock Options Plan, 2012 (ESOP 2012).
- 6 The Company has only one reportable segment i.e. Agrochemicals.
- 7 Figures of the previous year/period have been regrouped/rearranged, wherever necessary.
- 8 Exceptional items for the Year Ended 31st March, 2016 of Rs.1,697.99 Lac consists of excise settlement fees of Rs.114.69 Lac, obsolete inventory written off of Rs.213.14 Lac, debtors written off of Rs.170.37 Lac, loss on account of fixed assets & capital work-in-progress of Rs.727.82 Lac, provision for doubtful government receivables of Rs.97.91 Lac, government receivables written off of Rs.189.62 Lac and provision for doubtful debts of Rs.184.42 lac. The same for the quarter ended consists of loss on account of fixed assets & capital work-in-progress of Rs.274.67 Lac.
- 9 Extra-ordinary items for Year Ended 31st March, 2016 mainly consist of interest on income tax of Rs.98 Lac, bank charges of Rs.20 Lac, Excise Duty of Rs.13.77 Lac net off export incentive of Rs.81.54 Lac. The same for Quarter Ended 31st March, 2016 includes prior period items, being reversal of excess provision of Rs.27.83 Lac.

For Astec LifeSciences Limited

Sd/-

(Ashok V Hiremath)

Managing Director

Wednesday, 4th May, 2016

Astec LifeSciences Limited**Statement of Assets and Liabilities(Standalone) as at 31st March, 2016**

	(Rs. in Lac)	
	31 March, 2016	31 March, 2015
I. Equity and liabilities		
Shareholders' funds		
Share capital	1,945.51	1,945.51
Reserves and surplus	9,760.07	11,705.64
	11,705.57	13,651.14
Non-current liabilities		
Long-term borrowings	791.36	1,262.40
Deferred tax liabilities (Net)	874.19	559.45
Other long term liabilities	2,808.68	2,910.19
Long-term Provisions	44.92	74.08
	4,519.15	4,806.12
Current liabilities		
Short-term borrowings	10,862.23	7,257.21
Trade payables	7,542.59	7,900.39
Other current liabilities	2,415.05	1,728.25
Short-term provisions	30.79	452.14
	20,850.65	17,337.98
Total	37,075.37	35,795.24
II. Assets		
Non-current assets		
Fixed assets		
Tangible Assets	12,324.78	12,422.89
Intangible Assets	163.93	300.48
Capital work-in-progress	1,819.17	1,136.88
Intangible Asset under Development	165.60	87.83
	14,473.49	13,948.08
Non-current investments	49.81	99.81
Long-term loans and advances	3,044.00	2,110.42
Other Non Current assets		
	17,567.31	16,158.31
Current assets		
Current investments	0.10	9.17
Inventories	6,395.91	6,239.83
Trade receivables	9,484.49	9,880.50
Cash and Bank Balances	601.05	1,121.61
Short-term loans and advances	3,026.52	2,385.82
	19,508.07	19,636.93
Total	37,075.37	35,795.24

For Astec LifeSciences Limited

Sd/-

(Ashok V Hiremath)

Managing Director

Wednesday, 4th May, 2016

Astec LifeSciences Limited
Statement of Assets and Liabilities (Consolidated) as at 31st March, 2016

	(Rs. in Lac)	
	31 March, 2016	31 March, 2015
I. Equity and liabilities		
Shareholders' funds		
Share capital	1,945.51	1,945.51
Reserves and surplus	9,739.33	11,588.13
	11,684.84	13,533.64
Minority Interest	8.95	5.09
Non-current liabilities		
Long-term borrowings	791.36	1,322.05
Deferred tax liabilities (Net)	877.31	520.96
Other long term liabilities	2,808.68	2,976.82
Long-term Provisions	44.92	74.08
	4,522.27	4,893.91
Current liabilities		
Short-term borrowings	10,819.43	7,738.46
Trade payables	7,586.73	8,784.12
Other current liabilities	2,483.25	763.62
Short-term provisions	35.46	471.75
	20,924.87	17,757.95
Total	37,140.92	36,190.59
II. Assets		
Non-current assets		
Fixed assets		
Tangible Assets	12,358.18	12,782.74
Intangible Assets	163.93	523.70
Capital work-in-progress	1,819.17	1,136.88
Intangible Asset under Development	165.60	87.83
	14,506.89	14,531.14
Non-current investments	0.93	2.38
Long-term loans and advances	3,011.32	1,306.15
Other Non Current assets	-	-
	17,519.14	15,839.67
Current assets		
Current investments	0.10	9.17
Inventories	6,446.27	7,192.94
Trade receivables	9,532.16	10,363.46
Cash and Bank Balances	604.82	1,202.00
Short-term loans and advances	3,038.43	1,583.34
	19,621.78	20,350.92
Total	37,140.92	36,190.59

For Astec LifeSciences Limited

Sd/-
(Ashok V Hiremath)
Managing Director
Wednesday, 4th May, 2016

C. A. P.M. KATHARIYA

B.Com., LLB., (Gen.), FCA

C. A. HEMANT S. MAHAVAR

B.Com., FCA

C.A. RONAK N. DHARNIDHARKA

B.Com., ACA

C.A. PRATIK M. CHOUDHARY

B.Com., ACA



SHAH & KATHARIYA
CHARTERED ACCOUNTANT

Room No. 6, Kermani Building, 4th Floor,
27, Sir P. M. Road, Fort, Mumbai - 400 001.

Ph. : 6631 5862 Fax : 2285 6615 R. : 2872 8803

Mobile : 98210 34665 / 99872 49694 / 705

E-mail : office@shahkathariya.com

Web. : www.shahkathariya.com

Auditor's Report on Quarterly Financial Results and Year to Date Results of Astec LifeSciences Limited Pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF

ASTEC LIFESCIENCES LIMITED

We have audited the accompanying Statement of Standalone Financial Results of **Astec LifeSciences Limited** ("the company") for the year ended March 31, 2016 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the company's Management and approved by the board of Directors, has been prepared on the basis of the related financial statements which is in accordance with the accounting Standards prescribed under section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

We conducted our audit in accordance with the standards on auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal controls relevant to the Company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

In our opinion and to the best of our information and according to the explanations given to us the statement:


- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and



- (ii) gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India, of the net loss and other financial information of the Company for the year ended March 31, 2016.

The Statement includes the results for the Quarter ended March 31, 2016 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **Shah & Kathariya**
Chartered Accountants
Firm's Registration No.: 115171W



Per **P M Kathariya**
Partner
Membership No.: 031315

Place: Mumbai
Date: 04th May 2016



C. A. P.M. KATHARIYA

B.Com., LLB., (Gen.), FCA

C. A. HEMANT S. MAHAVAR

B.Com., FCA

C.A. RONAK N. DHARNIDHARKA

B.Com., ACA

C.A. PRATIK M. CHOUDHARY

B.Com., ACA



SHAH & KATHARIYA
CHARTERED ACCOUNTANT

Room No. 6, Kermani Building, 4th Floor,
27, Sir P. M. Road, Fort, Mumbai - 400 001.

Ph. : 6631 5862 Fax : 2285 6615 R. : 2872 8803

Mobile : 98210 34665 / 99872 49694 / 705

E-mail : office@shahkathariya.com

Web. : www.shahkathariya.com

Auditor's Report on Quarterly Consolidated Financial Results and Consolidated Year to Date Results of Astec LifeSciences Limited Pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF

ASTEC LIFESCIENCES LIMITED

We have audited the accompanying Statement of Consolidated Financial Results of **Astec LifeSciences Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the year ended March 31, 2016 ("the statement"), being submitted by the Holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Holding Company's Management and approved by the board of Directors, has been prepared on the basis of the related consolidated financial statements which is in accordance with accounting standards, prescribed under section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

We conducted our audit in accordance with the standards on auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Holding Company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



In our opinion and to the best of our information and according to the explanations given to us, the statement:

(a) includes the quarterly and year to date financial results of the following entities.

- (i) Astec LifeSciences Limited
- (ii) Behram Chemicals Private Limited
- (iii) Astec Crop Care Private Limited
- (iv) Astec Europe Sprl
- (v) Comercilizadora Agricola Agroastrachem Cia Ltda

(b) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and


(c) gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India, of the consolidated net loss and other financial information of the Group for the year ended March 31, 2016.

The consolidated financial results includes the unaudited financial statements of three subsidiaries whose financial statements reflect total assets of Rs. 110.83 Lacs as at March 31, 2016, total revenue of Rs. 1771.95 Lacs for the year ended March 31, 2016, and total loss after tax of Rs.17.04 Lacs for the year ended March 31, 2016, as considered in the consolidated financial results. Our opinion on the statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited financial statements.

For **Shah & Kathariya**

Chartered Accountants

Firm's Registration No.: 115171W



Per **P M Kathariya**

Partner

Membership No.: 031315



Place: Mumbai

Date: 04th May 2016





Astec LifeSciences Ltd.

FORM A

(For audit report with unmodified opinion)

[Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

1.	Name of the Company	Astec LifeSciences Limited
2.	Annual financial statements for the year ended	31 st March, 2016 (Standalone)
3.	Type of Audit Observation	Un- modified
4.	Frequency of observation	Not Applicable
5.	Signed by:	
	Ashok V. Hiremath (Managing Director)	
	Ravindra Inani (Chief Financial Officer)	
	Sitendu Sharma (Chairman of Audit Committee)	
	For M/s. Shah & Kathariya Chartered Accountants Firm Registration No. 115171W (Statutory Auditors)	 (P. M. Kathariya) Partner Membership No. 031315

Date: 4th May, 2016

Place: Mumbai



Regd. Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone : +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail : info@astecsl.com
Website : www.astecsl.com
CIN : L99999MH1994PLC076236





Astec LifeSciences Ltd.

FORM A

(For audit report with unmodified opinion)

[Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

1.	Name of the Company	Astec LifeSciences Limited
2.	Annual financial statements for the year ended	31 st March, 2016 (Consolidated)
3.	Type of Audit Observation	Un- modified
4.	Frequency of observation	Not Applicable
5.	Signed by:	
	Ashok V. Hiremath (Managing Director)	
	Ravindra Inani (Chief Financial Officer)	
	Sitendu Sharma (Chairman of Audit Committee)	
	For M/s. Shah & Kathariya Chartered Accountants Firm Registration No. 115171W (Statutory Auditors)	 (P. M. Kathariya) Partner Membership No. 031315

Date: 4th May, 2016

Place: Mumbai



Regd. Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001. India
Phone: +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail: info@astecsl.com
Website : www.astecsl.com
CIN : L99999MH1994PLC076236